Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hasan Tahir, Arumugam Moorthy & Antoni Chan. (2020) Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives. Open Access Rheumatology: Research and Reviews 12, pages 277-292.
Read now
Read now
Eric Toussirot. (2017) New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Expert Opinion on Pharmacotherapy 18:3, pages 275-282.
Read now
Read now
Jürgen Braun, Xenofon Baraliakos & Uta Kiltz. (2016) Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 16:5, pages 711-722.
Read now
Read now
Michael Roman, Vandana K Madkan & Melvin W Chiu. (2015) Profile of secukinumab in the treatment of psoriasis: current perspectives. Therapeutics and Clinical Risk Management 11, pages 1767-1777.
Read now
Read now
Articles from other publishers (26)
Randy Q. Cron, Peter Weiser & Timothy Beukelman. 2023. Clinical Immunology. Clinical Immunology
693
703
.
Berkan Armağan, Levent Kılıç, Bayram Farisoğulları, Gözde Kübra Yardımcı, Emre Bilgin, Ertuğrul Çağrı Bölek, Ömer Karadağ, Şule Apraş Bilgen, Sedat Kiraz, İhsan Ertenli & Umut Kalyoncu. (2022) Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis. Rheumatology International 43:1, pages 147-156.
Crossref
Crossref
Zhussipbek Mukhatayev, Aigul Sharip, Ayaulym Nurgozhina, Darya Chunikhina, Dimitri Poddighe, Bayan Ainabekova, Almagul Kushugulova & Jeannette Kunz. 2022. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases
419
458
.
Sara Assadiasl & Narjes Soleimanifar. 2022. Ankylosing Spondylitis - Axial Spondyloarthritis. Ankylosing Spondylitis - Axial Spondyloarthritis
3
21
.
Helou Zhang, Yang Yu, Weibin Du, Fengqing Wu, Yang Zheng, Conglin Ren, Huateng Zhou, Yijiang Wu, Yang Gao, Weifan Ren & Renfu Quan. (2021) Efficacy and Safety of Wenbu Zhibi Granule in Patients with Ankylosing Spondylitis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-9.
Crossref
Crossref
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, Atul Deodhar, Mikkel Østergaard, Ayan Das Gupta, Shephard Mpofu, Todd Fox, Adam Winseck, Brian Porter, Abhijit Shete & Lianne S. Gensler. (2021) Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. The Journal of Rheumatology 48:8, pages 1251-1258.
Crossref
Crossref
Zaarour Nancy, Li Yan, Shi Hui, Bowness Paul & Chen Liye. (2021) From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery. Frontiers in Immunology 12.
Crossref
Crossref
Matteo Vecellio, Vivien Xanath Hake, Connor Davidson, Maria Cristina Carena, B. Paul Wordsworth & Carlo Selmi. (2021) The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Frontiers in Immunology 11.
Crossref
Crossref
Balaji Zacharia & Antony Roy. 2020. Connective Tissue Disease - Current State of the Art. Connective Tissue Disease - Current State of the Art.
Helena Marzo-Ortega, Joachim Sieper, Alan J Kivitz, Ricardo Blanco, Martin Cohen, Karel Pavelka, Eumorphia M Delicha, Anna Stefanska, Hanno B Richards & Susanne Rohrer. (2020) 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. The Lancet Rheumatology 2:6, pages e339-e346.
Crossref
Crossref
Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards & Susanne Rohrer. (2020)
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3
MEASURE
3 Study
. ACR Open Rheumatology 2:2, pages 119-127.
Crossref
Crossref
Jacques Morel & Denis Mulleman. (2020) Rhumatologie, la multitude des options. médecine/sciences 35:12, pages 1029-1033.
Crossref
Crossref
Xenofon Baraliakos, Juergen Braun, Atul Deodhar, Denis Poddubnyy, Alan Kivitz, Hasan Tahir, Filip Van den Bosch, Evie-Maria Delicha, Zsolt Talloczy & Anke Fierlinger. (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5:2, pages e001005.
Crossref
Crossref
Randy Q. Cron, Peter Weiser & Timothy Beukelman. 2019. Clinical Immunology. Clinical Immunology
723
733.e1
.
Fatemeh Navid, Gerlinde Layh-Schmitt, Keith A. Sikora, Antony Cougnoux & Robert A. Colbert. (2018) The Role of Autophagy in the Degradation of Misfolded HLA-B27 Heavy Chains. Arthritis & Rheumatology 70:5, pages 746-755.
Crossref
Crossref
Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie & Brian Porter. (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Masaru Ishii. (2017) Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23. British Journal of Pharmacology 174:13, pages 1875-1880.
Crossref
Crossref
H. Marzo‐Ortega, J. Sieper, A. Kivitz, R. Blanco, M. Cohen, R. Martin, A. Readie, H. B. Richards & B. Porter. (2017) Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care & Research 69:7, pages 1020-1029.
Crossref
Crossref
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Dominique Baeten, Joachim Sieper, Paul Emery, Aimee Readie, Ruvie Martin, Shephard Mpofu & Hanno B Richards. (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases 76:6, pages 1070-1077.
Crossref
Crossref
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni & Daniella M. Schwartz. (2017) JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:5, pages 521-546.
Crossref
Crossref
Alistair Tindell, Hanna Johnsson & Iain B. McInnes. 2017. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
571
583
.
Carla C. Baan, Nynke M. Kannegieter, Claudia Rosso Felipe & Helio Tedesco Silva. (2016) Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation. Transplantation 100:9, pages 1833-1839.
Crossref
Crossref
Hye Won Kim, Seong Ryul Kwon, Kyong-Hee Jung, Seong-Kyu Kim, Han Joo Baek, Mi Ryung Seo, So-Young Bang, Hye-Soon Lee, Chang-Hee Suh, Ju Yang Jung, Chang-Nam Son, Seung Cheol Shim, Sang-Hoon Lee, Seung-Geun Lee, Yeon-Ah Lee, Eun Young Lee, Tae-Hwan Kim & Yong-Gil Kim. (2016) Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. PLOS ONE 11:4, pages e0153816.
Crossref
Crossref
Sabrina Gmuca & Pamela F. Weiss. (2015) Evaluation and Treatment of Childhood Enthesitis-Related Arthritis. Current Treatment Options in Rheumatology 1:4, pages 350-364.
Crossref
Crossref
Nelly Ziadé. (2015) Axial Spondyloarthritis: An Evolving Concept. EMJ Rheumatology, pages 98-102.
Crossref
Crossref
NAOTO TAMURA & KURISU TADA. (2015) Current Status of and Future Perspectives on Biologics in Rheumatic Diseases. Juntendo Medical Journal 61:6, pages 573-579.
Crossref
Crossref